A detailed history of China Universal Asset Management Co., Ltd. transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 10,344 shares of PRTA stock, worth $144,919. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,344
Previous 6,318 63.72%
Holding current value
$144,919
Previous $130,000 33.08%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$16.73 - $24.79 $67,354 - $99,804
4,026 Added 63.72%
10,344 $173,000
Q2 2024

Jul 19, 2024

SELL
$19.54 - $26.15 $78,980 - $105,698
-4,042 Reduced 39.02%
6,318 $130,000
Q1 2024

Apr 29, 2024

BUY
$24.75 - $40.66 $102,885 - $169,023
4,157 Added 67.02%
10,360 $257,000
Q4 2023

May 21, 2024

SELL
$32.31 - $52.32 $134,312 - $217,494
-4,157 Reduced 40.13%
6,203 $225,000
Q4 2023

Jan 23, 2024

BUY
$32.31 - $52.32 $155,992 - $252,600
4,828 Added 351.13%
6,203 $225,000
Q3 2023

May 21, 2024

BUY
$47.3 - $70.6 $32,353 - $48,290
684 Added 98.99%
1,375 $66,000
Q3 2023

Oct 30, 2023

BUY
$47.3 - $70.6 $32,353 - $48,290
684 Added 98.99%
1,375 $66,000
Q2 2023

May 21, 2024

SELL
$48.26 - $78.59 $1,013 - $1,650
-21 Reduced 2.95%
691 $47,000
Q2 2023

Jul 27, 2023

SELL
$48.26 - $78.59 $1,013 - $1,650
-21 Reduced 2.95%
691 $47,000
Q1 2023

May 21, 2024

BUY
$46.97 - $58.27 $10,380 - $12,877
221 Added 45.01%
712 $34,000
Q1 2023

Apr 27, 2023

BUY
$46.97 - $58.27 $10,380 - $12,877
221 Added 45.01%
712 $35,000
Q4 2022

May 21, 2024

SELL
$52.05 - $65.0 $513,681 - $641,485
-9,869 Reduced 95.26%
491 $29,000
Q4 2022

Jan 31, 2023

BUY
$52.05 - $65.0 $2,706 - $3,380
52 Added 11.85%
491 $30,000
Q3 2022

Oct 21, 2022

BUY
$25.16 - $60.63 $11,045 - $26,616
439 New
439 $27,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $657M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.